ArticleNeurosurgical review2025
One-year outcomes of the drug eluting stent in the treatment of severe vertebral artery ostium stenosis: single-center experience.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sirolimus Drug-Eluting Stent (DES) in vertebral artery ostial stenosis: insights from a multicenter analysis.Neuroradiology · 2026Article
- Clinical efficacy of drug-eluting stents in the treatment of vertebral artery stenosis and analysis of factors contributing to stent restenosis.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
background and purposeThe Maurora stent (Drug eluting stent) is the first rapamycin-eluting vertebral artery stent system, and currently, there are no studies on the one-year outcomes of the Maurora stent in the treatment of severe vertebral artery ostium stenosis. Therefore, this study utilizes Cumulative sum (CUSUM) curve analysis to evaluate the one-year prognosis and restenosis rate of the Maurora stent in patients with severe stenosis at the vertebral artery origin.
methodsAll patients were arranged in chronological order according to the sequence of their surgeries. CUSUM analysis was employed to assess the surgical learning curve. The point at which the CUSUM learning curve begins to descend marks the number of cases required to achieve procedural proficiency; this point delineates the transition from the initial stable phase to the mature phase. Postoperative Modified Rankin Scale(mRS) and NIHSS scores are visualized using histograms.
resultsUltimately, 38 patients met the inclusion and exclusion criteria and were included in the analysis. At the 1-year follow-up, 89.47% of patients had an MRS score of 0, showing a statistically significant improvement compared to preoperative values (p < 0.05). The MRS scores at 1year post-procedure showed a statistically significant difference between the mature and stable groups (P < 0.05).
conclusionsThe study showed that the Maurora stent (Drug eluting stent) is safe and effective in treating severe vertebral artery ostium stenosis, offering significant clinical value.
Indexed as
Identifiers
40673988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.